Oncology

Elranatamab (Elrexfio)

Pfizer

BCMA × CD3 bispecific. FDA approved in R/R MM. MagnetisMM-5 Phase 3 (elranatamab ± daratumumab vs DPd) ongoing for earlier-line expansion.

Multiple Myeloma

Linked Studies

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Loading comments…

Also Known As

Other names

elranatamab